Camellia PLC
27 May 2004
Camellia Plc
Chairman's statement at AGM
I should now like to take this opportunity to bring shareholders up to date with
developments in the current year.
It is too early to make any pronouncements concerning the unexpected change of
government in India, but we would hope there will not be any major impact on our
operations. Our policy continues to be to make as high a quality of tea as
possible, and whilst we are still awaiting the period of high production, the
prospects appear reasonable, as indeed they do for Bangladesh. The improved
political situation between India and Pakistan could, if maintained, have some
impact on tea exported to Pakistan from both Bangladesh and Kenya.
Tea production in our African operations has been reasonable and prices are up
to or even slightly ahead of budgeted figures in US dollar terms. However, the
South African Rand remains very strong and this is continuing to have an adverse
effect on our South African operations. We have now totally ceased our coffee
growing operations in Kenya and Malawi and discussions with potential partners
are at an advanced stage concerning the redeployment of the coffee land in Kenya
to alternative crops.
The Australian dollar has recently weakened against the US dollar and this
should make exports to the US for our citrus products slightly more competitive.
Australia does, however, continue to experience hot and dry weather conditions,
which could have a significant effect on production.
Prospects for the Malawi macadamia harvest in 2004 appear to be reasonably
positive with good production and beneficial prices. However, the dry weather in
South Africa will have a detrimental effect on production.
Brazil is experiencing another good year benefitting from the current high price
of soya.
Associated Cold Stores & Transport are still experiencing a highly competitive
market. Their results are disappointing, but further cost reduction measures are
being put in place. Our engineering companies are reporting greater activity in
the market place, but this has yet to show through in increased turnover and
profitability.
Siegfried are not immune from the present over capacity in the active
pharmaceutical ingredients market but are doing everything within their power to
fill their own capacity and reduce costs where appropriate. The generics part of
the business continues to perform well.
Duncan Lawrie continue to trade well in the first part of this year helped by
slightly higher lending rates, and increased activity in the investment market.
As usual it is impossible to anticipate with any certainty the likely results
for the first half of this year due to fluctuating commodity prices and
currencies.
For further enquiries please contact Camellia Plc
Malcolm Perkins
Tel: 01622 746655
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.